The U.S. Food and Drug Administration will make an announcement regarding imported infant formula as soon as later on May 16, the agency’s chief told NBC News in an interview as regulators and lawmakers seek to address ongoing supply shortages.
Although research is being conducted on Long COVID or Long COVID-19, whose symptoms continue for weeks and months after initial infection, there are very few ongoing clinical trials on treatments. Anecdotally, there has been what appears to be a successful treatment for Long Covid using Pfizer’s antiviral regimen Paxlovid.
Many countries around the world that appeared to have kicked COVID-19 are reporting surges, largely the result of the so-called “stealth” Omicron variant, BA.2.
In response to the ongoing Russian invasion of Ukraine, Pfizer will cease operations within Russia and proceeds from the company’s subsidiary in that country will be donated to provide direct humanitarian support to the people of Ukraine. Regarding COVID-19, Pfizer Chief Executive Officer Albert Bourla noted in an interview with Face the Nation that it is likely that a fourth booster shot of the company’s vaccine will be needed to fend off another surge of infections.
The CEO of Maryland-based Novavax believes U.S. Emergency Use Authorization (EUA) for the company’s protein-based COVID-19 vaccine could happen “within weeks.”
On the day the public and members of the U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee were going to get a look at Pfizer and BioNTech’s COVID-19 vaccine data for children under 5 years old, the companies pulled the Emergency Use Authorization (EUA) submission.
U.S. President Joe Biden on February 10 said mask requirements for children would likely to start to fall away given federal plans to begin vaccinating children under the age of 5, but said it was probably premature to drop COVID mask requirements entirely.
U.S. President Joe Biden on February 10 said he expected inflation to start to ease during 2022 as supply chain logjams clear up, while saying his administration was already helping ease shortages, as new data showed the biggest jump in consumer prices in 40 years.
The Biden administration is preparing for future variants of COVID-19, White House chief of Staff Ron Klain told MSNBC in an interview that aired on January 20 as the Omicron-related wave of cases appeared to be easing in parts of the United States.
Pfizer Inc. now expects to manufacture 80 million treatment courses of the company’s experimental COVID-19 antiviral drug, up from a previous forecast of 50 million, Chief Executive Officer Albert Bourla said in a CNBC interview on November 29.
